Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾Ï¿¡¼­ bcl-2 ¹× p53´Ü¹é ¹ßÇö¿¡ °üÇÑ ¿¬±¸ Study of bcl-2 and p53 Protein Expression in Prostatic Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 1È£ p.37 ~ 40
Àå¼®Èç, ¾ÈÀºÁÖ,
¼Ò¼Ó »ó¼¼Á¤º¸
Àå¼®Èç (  ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ °¡Á¤°úÇдëÇÐ ½ÄÇ°¿µ¾çÇаú

¾ÈÀºÁÖ (  ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±¾ÏÀº ºóµµ¸é¿¡¼­ ¼­±¸¿¡¼­´Â ³²¼º ºñ´¢±â°è Á¾¾çÀÇ ¼±µÎ¸¦ Â÷ÁöÇÏ°í ÀÖÀ¸¸ç, ¿ì¸®
³ª¶ó¿¡¼­´Â ¹æ±¤¾Ï°ú ½ÅÀå¾Ï¿¡ ÀÌ¾î ¼¼ ¹ø°·Î ¸¹ÀÌ ¹ß»ýÇÏ´Â Á¾¾çÀ¸·Î¼­ Áö¼ÓÀûÀÎ Áõ°¡ Ãß
¼¼¸¦ º¸ÀÌ´Â °ÍÀº »ç½ÇÀÌ´Ù.
Àü¸³¼±¾ÏÀÇ ¹ß»ýÀÌ º¹ÇÕÀûÀÎ ÀÎÀÚ¿¡ ÀÇÇØ ±âÀÎÇϵíÀÌ ±× ¿¹ÈÄ ¶ÇÇÑ º¹ÀâÇÑ ¿äÀεé°ú °ü·Ã
µÇ¾î ÀÖ´Ù. ÀÓ»ó°æ°ú°¡ ȯÀÚ¿¡ µû¶ó »óÀÌÇÑ Çö»óÀº ¿©·¯ ¾ÏµéÀÇ °øÅëµÈ Ư¡ÀÌÁö¸¸ Àü¸³¼±
¾ÏÀÌ Áö´Ï´Â Ư¼ºÀ» ¿©·¯ °¢µµ¿¡¼­ °üÂûÇÏ¸é »ó´çÈ÷ ¸¹Àº ¿¹ÈÄÀÎÀÚµéÀ» ¹ß°ßÇÒ ¼ö ÀÖÀ¸¸ç,
ÀÌ·¯ÇÑ ¿¹ÈÄÀÎÀÚµéÀÇ ºÐ·ù´Â »ýÁ¸À² ¹× Àç¹ßÀ²ÀÇ ¿¹Ãø»Ó¸¸ ¾Æ´Ï¶ó ¼ö¼ú ÈÄ Ãß°¡ÀûÀÎ Ä¡·á¸¦
°áÁ¤ÇÏ´Â ÆÇ´ÜÀÎÀڷεµ Àû¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ´õ Å« Àǹ̰¡ ÀÖ´Ù.
ÀÌÀüÀÇ Á¾¾ç¹ß»ý¿¡ °üÇÑ ¿¬±¸°¡ ¼¼Æ÷Áõ½ÄÀÇ ÀÌ»ó¿¡ ÁÖ·Î ÃÊÁ¡À» ¸ÂÃß¾úÀ¸³ª, ÃÖ±Ù¿¡´Â ¼¼
Æ÷ÀÇ »ç¸Á¿¡ °üÇÑ Á¶Àý ÀÌ»óÀÌ ¾Ï ¹ß»ý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í ÁßÀÇ Çϳª·Î ¹Þ¾Æµé¿©Áö°í
ÀÖ´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷°í»ç °úÁ¤À» ÃËÁø ¶Ç´Â ¾ïÁ¦½ÃÅ°´Âµ¥ °ü¿©ÇÏ´Â À¯ÀüÀÚµéÀÌ ÃÖ±Ù¿¡ ¹àÇôÁ³
´Ù ±× Áß bcl-2 À¯ÀüÀÚ´Â »ç¶÷ÀÇ 18¹ø ¿°»öü¿¡ À§Ä¡ÇÏ´Â ¿øÁ¾¾ç À¯ÀüÀڷμ­ ¼¼Æ÷°í»ç °úÁ¤
À» ¹æÇØÇÏ¿© ¼¼Æ÷ÀÇ »ýÁ¸À» ¿¬Àå½ÃÄÑ Á¶Á÷ÀÇ ¾Ç¼º º¯È­ ¹× ÁøÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸
·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, p53À¯ÀüÀÚ´Â »ç¶÷ÀÇ 17¹ø ¿°»öü¿¡ Á¸ÀçÇϸ鼭 ¼¼Æ÷ÀÇ ºÐÈ­ ¹× Áõ½ÄÀ»
Á¶ÀýÇÏ´Â Á¾¾ç¾ïÁ¦ À¯ÀüÀÚÀε¥ ¹ÝÇØ p53À¯ÀüÀÚ°¡ µ¹¿¬º¯ÀÌ°¡ ÀϾ¸é ¾ÏÀÇ ¹ß»ý ¹× ÁøÇà
¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ¿¡ ÀúÀÚµéÀº Àü¸³¼±¾Ï¿¡ À־ bcl-2 À¯Àü
ÀÚ¿Í p53 À¯ÀüÀÚÀÇ ¹ßÇö ¾ç»óÀ» °üÂûÇÏ¿© ¿¹ÈÄ ÀÎÀڷμ­ÀÇ »ç¿ë °¡´É¼º¿¡ ´ëÇØ ¾Ë¾Æº¸±â
À§ÇØ ¸é¿ªÁ¶Á÷ÇÐÀû ¹æ¹ýÀ» ÀÌ¿ëÇÏ¿´´Ù
#ÃÊ·Ï#
Purpose: bcl-2 and p53 are known to act as a regulator of apoptosis in prostatic
cancer and we evaluated the significance of these gene expressions and correlation with
prognostic factors in prostatic cancer
Materials and Methods: Forty-five formalin-fixed and paraffin-embedded samples of
histologically confirmed prostatic cancer, examined using immunohistochemical staining
for the two gene products and the expression related to the grade and stage.
Results; We found that positive staining for bel-2 was 46.7%(21/45) and p53 was
31.8%(17/45). As compared to the Gleason grade, positive staining for bel-2 and p53
was 14.3%(2/14), 7.1%(1/14) at low grade, 40.0%(6/15), 40.0% (6/15) at intermediate
grade, 81.3%(13/16), 62.5%(10/16) at high grade, respectively. It was significant
difference(p<0.05). And, as compared to the stage, positive staining for bel-2 and p53
was 0%(0/7), 0%(0/7) at stage A, 33.3%(4/12), 16.7%(2/12) at stage B, 54.5%(6/11),
45.5%(5/11) at stage C, 73.3%(11/15), 66.7%(10/l5) at stage D, respectively. It was
significant difference (p<0.05).
Conclusions: These results suggest that bcl-2 and p53 expression are associated with
the grade and stage of prostatic cancer, and to use them as the prognostic factor of
prostatic canecr, further study is needed at the molecular level.

Å°¿öµå

Prostatic cancer; bcl-2; p53;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS